Ionis Pharmaceuticals, Inc. (IONS) |
|
45.36 -0.9 (-1.95%)
|
09-29 16:00 |
|
Open: |
47 |
Pre. Close: |
46.26 |
|
High:
|
47 |
Low:
|
45.22 |
|
Volume:
|
1,338,005 |
Market Cap:
|
6,501(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:28:22 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 55.73 One year: 65.09 |
| Support: |
Support1: 42.37 Support2: 39.08 |
| Resistance: |
Resistance1: 47.71 Resistance2: 55.73 |
| Pivot: |
43.72  |
| Moving Average: |
MA(5): 45.53 MA(20): 42.85
MA(100): 40.76 MA(250): 39.83 |
| MACD: |
MACD(12,26): 1.3 Signal(9): 1 |
| Stochastic oscillator: |
%K(14,3): 80.2 %D(3): 85 |
| RSI: |
RSI(14): 64 |
| 52-week: |
High: 47.74 Low: 32.68 |
| Average Vol(K): |
3-Month: 972 (K) 10-Days: 1,238 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IONS ] has closed below upper band by 25.1%. Bollinger Bands are 53.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
47.02 - 47.34 |
47.34 - 47.6 |
|
Low:
|
44.62 - 44.93 |
44.93 - 45.18 |
|
Close:
|
44.92 - 45.41 |
45.41 - 45.81 |
|
Company Description |
|
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. |
Headline News |
Mon, 02 Oct 2023
Q3 2023 EPS Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ ... - MarketBeat
Fri, 29 Sep 2023
Raymond James Initiates Coverage of Ionis Pharmaceuticals (IONS ... - Nasdaq
Thu, 28 Sep 2023
Eplontersen Phase 3 results published in JAMA show consistent ... - PR Newswire
Thu, 28 Sep 2023
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX ... - Nasdaq
Wed, 27 Sep 2023
Ionis enters agreement with Roche for two novel RNA-targeted ... - PR Newswire
Tue, 26 Sep 2023
Analyst Rating: Will Ionis Pharmaceuticals Inc (IONS) Stock Lead the Market? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
143 (M) |
| Shares Float |
142 (M) |
|
% Held by Insiders
|
0.7 (%) |
|
% Held by Institutions
|
95 (%) |
|
Shares Short
|
9,290 (K) |
|
Shares Short P.Month
|
9,210 (K) |
Stock Financials |
|
EPS
|
-2.18 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.99 |
|
Profit Margin (%)
|
-49.1 |
|
Operating Margin (%)
|
-74.5 |
|
Return on Assets (ttm)
|
-10.9 |
|
Return on Equity (ttm)
|
-58.8 |
|
Qtrly Rev. Growth
|
40.7 |
|
Gross Profit (p.s.)
|
-1.8 |
|
Sales Per Share
|
4.39 |
|
EBITDA (p.s.)
|
-3.18 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-456 (M) |
|
Levered Free Cash Flow
|
-269 (M) |
Stock Valuations |
|
PE Ratio
|
-20.91 |
|
PEG Ratio
|
0.2 |
|
Price to Book value
|
15.17 |
|
Price to Sales
|
10.31 |
|
Price to Cash Flow
|
-14.26 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
